Small molecule · Inhibitor of poly(ADP-ribose) glycohydrolase (PARG) · developed by IDEAYA Biosciences
IDE161 is an orally bioavailable small molecule that inhibits poly(ADP-ribose) glycohydrolase (PARG), the enzyme that hydrolyzes poly(ADP-ribose) chains produced by PARP1. By blocking PAR chain hydrolysis, it attenuates DNA repair and induces mitotic arrest. It is being studied in advanced or metastatic solid tumors, including breast, ovarian, prostate, endometrial, colorectal and head and neck cancers, and small cell and neuroendocrine lung carcinomas.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07174583 | Phase 1/2 | Small-cell Lung Cancer | Recruiting | IDYA |
| NCT05787587 | Phase 1 | Advanced or Metastatic Solid Tumors | Active not recruiting | IDYA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced or Metastatic Solid TumorsBreast CancerColorectal CancerEndometrial CancerExtensive Stage Small Cell Lung Cancer (ES-SCLC)Head and Neck CancersNeuroendocrine CarcinomasNSCLCOvarian CancerProstate CancerSmall-cell Lung CancerSolid Tumor Show to Express DLL3
See IDYA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IDYA catalysts and pipeline →